Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
ILLUSIO is a plastic surgery simulation tool that enables a surgeon and patient to...
ILLUSIO is a plastic surgery simulation tool th...
Translate Bio is a leading mRNA therapeutics company developing a new class of pot...
Translate Bio is a leading mRNA therapeutics co...
Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...
Allogene Therapeutics is a clinical stage biote...
Celyad is a biopharmaceutical company, specialized in CAR-T cell therapy, that is ...
Celyad is a biopharmaceutical company, speciali...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Ra PharmaÂŽ is a clinical-stage biopharmaceutical company using a proprietary pept...
Ra PharmaÂŽ is a clinical-stage biopharmaceutic...
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the develop...
Aridis Pharmaceuticals, Inc. is a biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.